AstraZeneca pill slashes lung cancer progression in study

LONDON, Dec 6 (Reuters) - AstraZeneca's pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial, lifting prospects for a drug that is key to the company's ambitious long-term sales goals.